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In recent months, an outbreak of interstitial pneumonia (SARS-CoV-2) known as COVID-19 that started in Wuhan (China) has been affecting the world\'s population [@b0005]. COVID-19 causes acute respiratory distress syndrome (ARDS), a disease where the lungs are unable to provide enough oxygen for the body [@b0010]. Indeed, SARS patients have been shown acute inflammation with pulmonary edema, pleural effusions, focal bleeding and mucopurulent material in the trachea-bronchial tree [@b0015]. In addition, other changes may occur, including hyaline membrane formation, alveolar hemorrhage, and fibrin exudation in alveolar spaces with alveolar fibrosis which appears during the later stages [@b0020]. Histological examination of the lungs of patients who died of SARS revealed extensive immune cell infiltration in the interstitium and alveoli [@b0025]. Indeed, coronavirus infection causes a severe inflammatory response in the lung, accompanied by interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes [@b0030]. The innate immune response signaling cascade starts with the recognition of pathogen-associated molecular patterns by pattern recognition receptors (PRRs). For RNA viruses in the lungs, the Toll-like receptors (TLRs) 3, 4, 7 and 8, which are expressed on several immune cells, are important PRRs [@b0035]. Also, intracellular cytosolic PRRs such as MDA5 and RIG-I, which are present in virtually any cell type including those of the lung, have been shown to be relevant for respiratory infections [@b0040]. In this way, the innate immune system induces transcription factors in the nucleus which in turn stimulate expression of types I and III interferons (IFNs) and other proinflammatory cytokines [@b0045].

Mast cells (MC) are strategically placed at sites that interface with external environment of the body such as the skin, lung, and intestines [@b0050]. Within such tissues they are predominately below the epithelial layer and closely associated with blood vessels. This location allows them to act as sentinels for tissue damage and pathogen invasion [@b0055]. Indeed, in vitro and in vivo studies demonstrated that mast cells are able to detect DAMPS from a number of viruses including respiratory syncytial virus (RSV), rhinovirus (RV), reovirus, dengue virus (DENV), human immunodeficiency virus (HIV) and influenza [@b0060]. Hu et al., 2012 were the first to demonstrate a direct involvement of MCs in viral infection, showing increased MCs numbers in the nasal mucosa, trachea, and lungs during the early stage of infection with H5N1 influenza virus in mice [@b0065]. Although there are no reports of MCs activation following SARS-CoV or MERS-CoV infection, activation has been observed both in vitro and in vivo following infection with influenza virus [@b0065] and may occur following other severe respiratory infections, including coronaviruses ([Fig. 1](#f0005){ref-type="fig"} ) [@b0070].Fig. 1Degranulation of Mast cells due to TLR-Antigen interaction.

Sodium Chromo-Glycate (SCG) is a natural antiallergic drug that is able to stabilize MCs membranes. Further studies demonstrated that SCG can inhibit degranulation and the release of cytokines and inflammatory mediators from MCs [@b0075]. Interestingly, it has been investigated the role of SCG as protective factor during the initial process of influenza virus infection and the possible mechanism behind any such effects in mouse model. It has been shown that SCG can improve the mouse survival and respiratory pathological changes. Although viral replication was not inhibited, SCG could regulate the expressions of IL-6, TNF-α, TLR3, and TRIF to alleviate the pathological injury to the nose, trachea, and lungs by reducing the inflammatory response [@b0080]. Palmitoylethanolamide (PEA) is another molecule that is involved in mast cells homeostasis and therefore could be of interest in the symptomatic treatment of viral pneumonia. The analgesic and anti-inflammatory action of PEA seems to involve different molecular actors. PEA inhibits the release of both preformed and newly synthesized mast cell mediators, such as histamine and TNF-α [@b0085]. It can down-regulate hyperactive mast cells in a dose-dependent manner [@b0090]. PEA reduces the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) which play a key role in regulating the immune response to infection. In 2013, a systematic review on randomized trials analyzed the efficacy and safety of PEA in the treatment of the common cold and influenza, establishing its protective effects on the respiratory tract during viral infections [@b0095]. Summarizing, to date, there is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. For these reasons, it is imperative to look for any other possible strategies that might help the physician in the correct management of these patients. SCG and PEA represent safe, low cost and well-known drugs that might be useful in the management of COVID 19 ([Fig. 2](#f0010){ref-type="fig"} ). Obviously, basic and clinical studies are necessary in order to evaluate SCG and PEA in the current clinical practice.Fig. 2PEA and SCG are able to inhibit degranulation of Mast cells and the release of proinflammatory mediators (i.e. caspase-1). PEA through indirect activation of CB2 receptors. Several mechanisms have been proposed for SCG. PEA: palmitoylethanolamide; SCG: sodium cromoglycate.
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